Mechanism of Retinoblastoma Tumor Cell Death after Focal Chemotherapy, Radiation, and Vascular Targeting Therapy in a Mouse Model

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33101, USA..
Investigative Ophthalmology &amp Visual Science (Impact Factor: 3.4). 01/2008; 48(12):5371-6. DOI: 10.1167/iovs.07-0708
Source: PubMed


To evaluate the mechanism and timing of retinal tumor cell death in the LH(BETA)T(AG) mouse model of retinoblastoma after treatment with vascular targeting therapies and conventional therapies (focal chemotherapy and radiation).
For vascular targeting therapy, 12- or 16-week-old mice were treated with a single subconjunctival injection of either anecortave acetate (300 microg) or combretastatin A4 (1.5 mg). Eyes were analyzed at 1 day and 1 week after treatment. Tumor cell death was evaluated using TUNEL assays or immunofluorescence analysis of activated caspase 3 to detect apoptosis. Histopathologic analysis was performed to identify areas of necrosis. For conventional therapy, LH(BETA)T(AG) mice were treated with six serial subconjunctival injections of focally delivered carboplatin chemotherapy (100 microg/delivery) or hyperfractionated external beam radiotherapy (EBRT; 15 Gy total dose). Cell death was analyzed by TUNEL assay.
The highest levels of apoptotic cell death were seen 1 day after treatment in all treatment groups compared with vehicle controls. At 1 week after treatment, apoptotic cell death remained significantly elevated in the EBRT and carboplatin groups, but not after vessel targeting therapy. No significant necrosis was detected by histology in tumors of treated or of control eyes.
Conventional therapies (focal carboplatin chemotherapy and EBRT) and vascular targeting agents significantly increase cell death through apoptosis, while not having a significant effect on necrosis in this murine model of retinoblastoma. These studies will aid in the optimization of delivery schemes of combined treatment modalities.

Download full-text


Available from: Brandy C. Hayden,
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter will review the clinical and histopathologic features associated with the presentation and diagnosis of retinoblastoma. A thorough appreciation of the differential and a detailed clinical assessments is the cornerstone of arriving at the proper diagnosis. Unlike most cancers, retinoblastoma is unique, as tissue is generally not necessary for diagnostic and treatment purposes. However, once the eye is enucleated, the histopathologic features guide therapy and prognosis. We will review ancillary testing that can assist the clinician and address pathologic features that can affect patient prognosis.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review highlights many of the most important articles published from June 2007 to May 2008 on retinoblastoma. Significant advances in molecular biology, translational research, and clinical reports are detailed. The most significant recent findings in the molecular biology of retinoblastoma include the evidence for aneuploidy and genomic instability as cancer causes rather than the long-held Knudson's 'two-hit' hypothesis; the evidence that retinoma may represent a precursor lesion for retinoblastoma prior to the acquisition of genomic instability; and the evidence that a horizontal interneuron may be the cell of origin in murine knockout retinoblastoma and may be capable of clonal expansion after differentiation. Translational studies also demonstrate promise for the use of topotecan and 2-deoxy-D-glucose in children. Finally, the introduction of intraarterial chemotherapy for human intraocular retinoblastoma appears to be safe and effective and may eliminate the need for enucleation in many patients. Exciting new advances in both the basic science and clinical applications of new therapies continue to emerge for this rare disease. We expect that local control rates even for advanced intraocular retinoblastoma will soon reach 100% in the developed world as a result of new findings in the clinic and in the laboratory.
    Current opinion in ophthalmology 12/2008; 19(6):526-34. DOI:10.1097/ICU.0b013e328312975b · 2.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic chemotherapy has become the cornerstone of therapy for retinoblastoma. The advent of novel chemotherapeutic and antiangiogenesis agents together with new routes of drug administration including periocular, intravitreal and intra-ophthalmic artery injection will hopefully revolutionize the management of this sight-threatening and potentially fatal infantile ocular neoplasm.
    07/2009; 4(3):169-73.
Show more